Alzheimer's drug MK-1167 gets first human test in healthy volunteers

NCT ID NCT07334860

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested two different forms of MK-1167, an experimental drug aimed at treating Alzheimer's symptoms, in 16 healthy adults. Researchers measured how the drug moves through the body and checked for safety. The goal is to find a safe dose before testing it in people with Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-1167
What this could lead to: If successful, this study could help determine a safe dose of MK-1167 for future trials in people with Alzheimer's disease.
What could go wrong: This is a very early, small study in healthy people, not patients. It only measures how the drug behaves in the body, not whether it works for Alzheimer's. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

QPS-MRA, LLC ( Site 0001)

South Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.